Kristensen, SL, Rørth, R, Jhund, PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7 (2019), 776–785.
Scheen, AJ, Semaglutide: a promising new glucagon-like peptide-1 receptor agonist. Lancet Diabetes Endocrinol 5 (2017), 236–238.
Aroda, VR, Ahmann, A, Cariou, B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes Metab 45 (2019), 409–418.
Mann, JFE, Hansen, T, Idorn, T, et al. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials. Lancet Diabetes Endocrinol 8 (2020), 880–893.
Frías, JP, Auerbach, P, Bajaj, HS, et al. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol, 2021 published online July 19. https://doi.org/10.1016/S2213-8587(21)00174-1.
Frías, JP, Bonora, E, Nevarez Ruiz, L, et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care 44 (2021), 765–773.
Davies, MJ, Bergenstal, R, Bode, B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes randomized clinical trial. JAMA 314 (2015), 687–699.
Davies, M, Færch, L, Jeppesen, OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 397 (2021), 971–984.
Marso, SP, Bain, SC, Consoli, A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
DeFronzo, RA, Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab 19 (2017), 1353–1362.
